SpyGlass Pharma

US · SGP #3415 by market cap Listed 2026

24.00 +0.10 +0.42%

Live - 5344 symbols - heartbeat 375s ago · 2026-10-08 09:53

After-hours 23.90 0.00%

Market cap: 802.75M
P/E (TTM): -14.32
P/B: 3.45
EPS: -1.19
Div yield: 0.00%
52W pos: 45%

Reader sentiment Are you bullish or bearish on SGP?

Anonymous reader poll. Unscientific, not investment advice.

About SpyGlass Pharma

SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA.

Founded: 2019
CEO: Mr. Patrick H. Mooney
Employees: 65
Headquarters: Aliso Viejo, California, United States of America
Fiscal year end: 12-31
Website: spyglasspharma.com

Company profile

Exchange: US
Symbol: SGP
Market-cap rank: #3415
Listing date: 2026-02-06
Market cap: 802.75M
Float cap: 155.91M
Shares out: 33.45M
Float shares: 6.50M

Sectors & themes

Biotechnology IPOs

Browse all sectors & themes

Quote time 2026-10-08 09:53:18 · For reference only, not investment advice and not tailored to your situation.